×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
OCGN – ocugen, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
OCGN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/23
07:02 am
ocgn
Ocugen to Present at April 2026 Investor and Industry Conferences
Low
Report
Ocugen to Present at April 2026 Investor and Industry Conferences
4/23
12:52 am
ocgn
Ocugen (OCGN) Valuation Check After Encouraging Phase 2 ArMaDa Results For OCU410 [Yahoo! Finance]
Low
Report
Ocugen (OCGN) Valuation Check After Encouraging Phase 2 ArMaDa Results For OCU410 [Yahoo! Finance]
4/21
04:27 am
ocgn
OCU410's Phase 2 Gene-Agnostic Results in Dry AMD Might Change The Case For Investing In Ocugen (OCGN) [Yahoo! Finance]
Medium
Report
OCU410's Phase 2 Gene-Agnostic Results in Dry AMD Might Change The Case For Investing In Ocugen (OCGN) [Yahoo! Finance]
4/5
12:37 am
ocgn
Evaluating Ocugen (OCGN) After Recent Share Price Swings And Gene Therapy Progress [Yahoo! Finance]
Low
Report
Evaluating Ocugen (OCGN) After Recent Share Price Swings And Gene Therapy Progress [Yahoo! Finance]
4/4
01:04 am
ocgn
Ocugen (OCGN) was downgraded by Wall Street Zen from "hold" to "sell"
Low
Report
Ocugen (OCGN) was downgraded by Wall Street Zen from "hold" to "sell"
4/1
07:18 am
ocgn
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease [Yahoo! Finance]
Medium
Report
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease [Yahoo! Finance]
4/1
07:16 am
ocgn
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease [TheStreet.com]
Low
Report
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease [TheStreet.com]
4/1
07:02 am
ocgn
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease
Low
Report
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/17
04:57 pm
ocgn
Form PRE 14A Ocugen, Inc. For: Jun 11
Medium
Report
Form PRE 14A Ocugen, Inc. For: Jun 11
4/14
06:38 pm
ocgn
Form SCHEDULE 13G Ocugen, Inc. Filed by: MILLENNIUM MANAGEMENT LLC
Medium
Report
Form SCHEDULE 13G Ocugen, Inc. Filed by: MILLENNIUM MANAGEMENT LLC
4/2
09:27 pm
ocgn
Form 4 Ocugen, Inc. For: Apr 01 Filed by: Zhang Junge
Low
Report
Form 4 Ocugen, Inc. For: Apr 01 Filed by: Zhang Junge
3/27
11:04 am
ocgn
Form SCHEDULE 13G/A Ocugen, Inc. Filed by: VANGUARD GROUP INC
Low
Report
Form SCHEDULE 13G/A Ocugen, Inc. Filed by: VANGUARD GROUP INC
3/27
06:02 am
ocgn
Form 8-K Ocugen, Inc. For: Mar 26
Medium
Report
Form 8-K Ocugen, Inc. For: Mar 26
3/24
12:02 pm
ocgn
Form 8-K Ocugen, Inc. For: Mar 24
Medium
Report
Form 8-K Ocugen, Inc. For: Mar 24
3/20
08:00 am
ocgn
Form 8-K Ocugen, Inc. For: Mar 12
High
Report
Form 8-K Ocugen, Inc. For: Mar 12
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
10/9
Ocugen Announces Share Repurchase Program
32.3%
1/3 Form 8-K Ocugen, Inc. For: Jan 01 31.4%
11/26 Form 8-K Ocugen, Inc. For: Nov 21 19.4%
12/13 Form 3 Ocugen, Inc. For: Sep 27 Filed by: Musunuri Shankar 13.8%
4/7 Ocugen Appoints Kirsten Castillo and Prabhavathi Fernandes to Board of Directors 12.6%
2/10 Ocugen to Present at NobleCon16 - Noble Capital Markets’ Sixteenth Annual Investor Conference 9.7%
5/1 Form 8-K Ocugen, Inc. For: Apr 30 8.0%
11/20 Form 4 Ocugen, Inc. For: Nov 18 Filed by: Zhang Junge 6.5%
10/15 Form 4 Ocugen, Inc. For: Oct 11 Filed by: Zhang Junge 6.3%
12/5 Form 4 Ocugen, Inc. For: Dec 04 Filed by: Zhang Junge 6.1%
1/3 Form 8-K Ocugen, Inc. For: Jan 01 31.4%
11/26 Form 8-K Ocugen, Inc. For: Nov 21 19.4%
12/13 Form 3 Ocugen, Inc. For: Sep 27 Filed by: Musunuri Shankar 13.8%
4/7 Ocugen Appoints Kirsten Castillo and Prabhavathi Fernandes to Board of Directors 12.6%
2/10 Ocugen to Present at NobleCon16 - Noble Capital Markets’ Sixteenth Annual Investor Conference 9.7%
5/1 Form 8-K Ocugen, Inc. For: Apr 30 8.0%
11/20 Form 4 Ocugen, Inc. For: Nov 18 Filed by: Zhang Junge 6.5%
10/15 Form 4 Ocugen, Inc. For: Oct 11 Filed by: Zhang Junge 6.3%
12/5 Form 4 Ocugen, Inc. For: Dec 04 Filed by: Zhang Junge 6.1%
TOP News Decliners
9/30
Ocugen Announces Completion of its Merger with Histogenics to Create Nasdaq-Listed Clinical-Stage Company Developing Novel Ocular Gene Therapies and Biotherapeutics
-59.3%
10/7 Form 8-K Ocugen, Inc. For: Oct 04 -33.7%
3/27 Ocugen Provides Business Update and Full Year 2019 Financial Results -23.1%
11/8 Ocugen Provides Business Update and Third Quarter 2019 Financial Highlights -21.3%
10/2 Form SC 13D/A Ocugen, Inc. Filed by: Wilmslow Estates Ltd -19.4%
11/12 Form 10-Q Ocugen, Inc. For: Sep 30 -18.1%
4/22 Form 8-K Ocugen, Inc. For: Apr 22 -15.0%
12/30 Ocugen (NASDAQ: OCGN) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -14.8%
11/8 Form DEF 14A Ocugen, Inc. For: Dec 18 -14.6%
10/9 Form 8-K Ocugen, Inc. For: Oct 08 -13.6%
10/7 Form 8-K Ocugen, Inc. For: Oct 04 -33.7%
3/27 Ocugen Provides Business Update and Full Year 2019 Financial Results -23.1%
11/8 Ocugen Provides Business Update and Third Quarter 2019 Financial Highlights -21.3%
10/2 Form SC 13D/A Ocugen, Inc. Filed by: Wilmslow Estates Ltd -19.4%
11/12 Form 10-Q Ocugen, Inc. For: Sep 30 -18.1%
4/22 Form 8-K Ocugen, Inc. For: Apr 22 -15.0%
12/30 Ocugen (NASDAQ: OCGN) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -14.8%
11/8 Form DEF 14A Ocugen, Inc. For: Dec 18 -14.6%
10/9 Form 8-K Ocugen, Inc. For: Oct 08 -13.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: